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Abstract
We sought to evaluate the reproducibility of a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based
approach to measure the stable-isotope enrichment of in vivo-labeled muscle ATP synthase b subunit (b-F1-ATPase), a
protein most directly involved in ATP production, and whose abundance is reduced under a variety of circumstances.
Muscle was obtained from a rat infused with stable-isotope-labeled leucine. The muscle was homogenized, b-F1-ATPase
immunoprecipitated, and the protein was resolved using 1D-SDS PAGE. Following trypsin digestion of the isolated protein,
the resultant peptide mixtures were subjected to analysis by HPLC-ESI-MS/MS, which resulted in the detection of multiple b-
F1-ATPase peptides. There were three b-F1-ATPase unique peptides with a leucine residue in the amino acid sequence, and
which were detected with high intensity relative to other peptides and assigned with .95% probability to b-F1-ATPase.
These peptides were specifically targeted for fragmentation to access their stable-isotope enrichment based on MS/MS peak
areas calculated from extracted ion chromatographs for selected labeled and unlabeled fragment ions. Results showed best
linearity (R2 = 0.99) in the detection of MS/MS peak areas for both labeled and unlabeled fragment ions, over a wide range of
amounts of injected protein, specifically for the b-F1-ATPase134-143 peptide. Measured stable-isotope enrichment was highly
reproducible for the b-F1-ATPase134-143 peptide (CV = 2.9%). Further, using mixtures of synthetic labeled and unlabeled
peptides we determined that there is an excellent linear relationship (R2 = 0.99) between measured and predicted
enrichment for percent enrichments ranging between 0.009% and 8.185% for the b-F1-ATPase134-143 peptide. The described
approach provides a reliable approach to measure the stable-isotope enrichment of in-vivo-labeled muscle b-F1-ATPase
based on the determination of the enrichment of the b-F1-ATPase134-143 peptide.
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Introduction
There are well-established approaches to measure the protein
synthesis in skeletal muscle using stable-isotope-labeled amino
acids [1]. These approaches are based on the in vivo-metabolic
labeling of proteins followed by the measurement of the stable-
isotope enrichment of, typically, a mixture of proteins using gas
chromatography-mass spectrometry (GC-MS). Measurement of
this enrichment provides the means to determine a global/average
rate of synthesis across proteins in skeletal muscle. Measurement of
the enrichment of a single protein that is present in small amounts
in skeletal muscle cannot, however, be practically performed using
these approaches because of the low mass sensitivity of the GC-
MS. Yet, it is the measurement of the enrichment at the individual
protein level that it is necessary for the determination of the rate of
synthesis of a specific protein.
At any time, muscle requires a continuous supply of energy in
the form of adenosine triphosphate (ATP), which supports various
metabolic processes within muscle and maintains muscle’s
function. The demand for ATP production in muscle increases
several-fold as a result of physical activity. More than 90% of ATP
in skeletal muscle is produced by the enzyme ATP synthase in
mitochondria. The beta subunit of the ATP synthase (b-F1-
ATPase) is important from a functional standpoint because it
forms the catalytic site of the enzyme, and thus has a key role in
determining the capacity for ATP production. In circumstances
associated with reduced capacity for ATP production in muscle,
such as obesity [2] and aging [3], reduced amounts of muscle b-
F1-ATPase have been reported [4,5]. Reduced amounts of b-F1-
ATPase have also been reported in liver and tumors in conditions
associated with hypothyroidism and cancer, respectively [6,7,8].
Understanding the mechanisms behind the reduced levels of b-
F1-ATPase in skeletal muscle requires knowledge of the rates of
synthesis/breakdown of b-F1-ATPase. In addition to maintaining
the quantity of muscle b-F1-ATPase, the rate of synthesis of b-F1-
ATPase plays a key role in maintaining the quality of protein by
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continuously renewing the b-F1-ATPase pool in skeletal muscle.
As a result of the latter process, older and/or damaged molecules
of the protein are replaced by de novo synthesized b-F1-ATPase
molecules. A key part in the overall process of determining the
kinetics of muscle b-F1-ATPase in association with the infusion of
stable-isotope amino acids is the ability to reliably measure the
stable isotope enrichment of b-F1-ATPase. Recently, Bateman
et al. [9] have described a liquid chromatography-tandem mass
spectrometry (LC-MS/MS) approach for the measurement of
amyloid-b stable-isotope enrichment from cerebrospinal fluid.
However, the applicability of this approach and its reproducibility
for the measurement of enrichment of a protein from skeletal
muscle, such as the muscle b-F1-ATPase, has not been evaluated.
Lower protein abundance and turnover rates, ultimately resulting
in lower levels of labeled proteins in skeletal muscle compared to
cerebrospinal fluid, as well as differences in the ionization of
protein-associated peptides and their fragmentation patterns, all
necessitate the need to evaluate the applicability of LC-MS/MS to
specifically measure the stable-isotope enrichment of muscle b-F1-
ATPase.
The overall goal of this research was, therefore, to determine the
reproducibility of an LC-MS/MS method for the measurement of
stable-isotope enrichment of in vivo-labeled muscle b-F1-ATPase.
We specifically sought to determine if there is a specific b-F1-
ATPase peptide that can provide reproducible measurements to
be used for the determination of b-F1-ATPase enrichment. The
following were evaluated for b-F1-ATPase tryptic-peptides
following isolation of b-F1-ATPase from rat skeletal muscle: 1)
the MS/MS signal linearity in the detection of labeled and
unlabeled fragment ions of b-F1-ATPase peptides over a range of
injected amounts of protein, 2) the reproducibility of the measured
enrichment across b-F1-ATPase peptides, and 3) the linearity in
the measured enrichment determined by using mixtures contain-
ing various ratios of labeled to unlabeled synthetic peptides for the
b-F1-ATPase peptide with the most reproducible measurement of
its enrichment.
Methods
Ethics statement
The study protocol and procedures were reviewed and
approved by the Institutional Animal Care and Use Committee
at Arizona State University (Protocol ID 07-939R).
Selection of the stable-isotope amino acid
L-[2,3,3,4,5,5,5,6,6,6-2H10]leucine, which is a stable-isotope of
the amino acid leucine was selected to label leucine residues in the
b-F1-ATPase for several reasons: 1) leucine is abundant in b-F1-
ATPase and this increases the chances for detecting leucine-
containing peptides that meet our criteria (discussed below); 2) the
specific stable-isotope of leucine has a mass that is large enough to
separate the isotope envelopes between labeled and unlabeled
peptides, allowing for easier identification; 3) although not the
focus of the present study, calculation of the rate of synthesis of a
protein requires determination of the precursor (i.e. leucine)
enrichment, which can be determined in a practical way when
using the selected stable-isotope of the amino acid leucine.
Specifically, in the selected d10-leucine, and as a result of the
transamination reaction, the deuterium attached to the alpha
carbon of the amino acid, as is also the case for the hydrogen for
endogenous leucine, is rapidly exchanged for hydrogen via alpha-
ketoisocaproic acid metabolism in vivo resulting in the production
of d9-leucine inside the cell [10]. That way, both unlabeled and
d9-labeled leucine are introduced intracellularly in the same way
before incorporation into the protein, and under these conditions
enrichment with labeled leucine that has undergone transamina-
tion measured in peripheral blood is the same as that measured in
muscle [1,11], allowing for a convenient and practical determi-
nation of the precursor enrichment.
Animals and infusion protocol
Muscle for the experiments was obtained from two adult male
Sprague-Dawley rats (Charles River, Wilmington, MA). Prior to
the collection of muscle, d10-leucine was infused (50 mg/kg/hour;
Cambridge Isotope Laboratories, Inc., Andover, MA) for seven
hours intravenously in one of the rats to increase the incorporation
of stable-isotope-labeled leucine into muscle b-F1-ATPase, while
the other rat received a comparable rate of infusion of saline.
Muscle homogenization, b-F1-ATPase
immunoprecipitation, SDS-PAGE, and in-gel digestion
procedures
Approximately 100 mg of vastus lateralis muscle was homoge-
nized in ice-cold freshly prepared buffer (1 mL/100 mg tissue;
20 mM Hepes pH 7.6, 1 mM EDTA pH 8.0, 250 mM sucrose,
5 mM NaF, 1 mM Na-pyrophosphate, 1 mM ammonium molyb-
date, 1 mM Na3VO4, 10 ug/ml aprotinin, 10 ug/ml leupeptin,
250uM PMSF) and centrifuged at 14,000 x g for 30 min at 4uC.
Aliquots of supernatant were stored at -80uC. Protein concentrations
in the homogenate were determined by the method of Lowry [12].
Muscle b-F1-ATPase was purified from the whole muscle
homogenate by immunoprecipitation (IP) using a mouse mono-
clonal b-specific antibody coupled to protein G agarose beads for
1 hr at room temperature. After antibody-bead conjugation, 2 mg
of muscle protein and adequate homogenization buffer was added
to the mixture which was incubated overnight on rotation in 4uC.
The beads were subsequently washed four times with ice-cold PBS
(pH 7.4) and the proteins were denatured and eluted from the
beads by incubation for 30 min at 37uC in 15 mL 2X SDS sample
loading buffer [13]. Proteins were then separated by 10% SDS-
polyacrylamide gel electrophoresis (PAGE) and visualized by
Coomassie blue staining (Sigma Chemical Co., St. Louis, MO).
The band corresponding to the weight of b-F1-ATPase
( = 56 kD) was excised from the gel and cut into 1 mm cubes.
Cubes from each lane were placed into microcentrifuge tubes and
washed with 400 uL of deionized water. Coomassie stain was
removed with 2 washes with 300 uL of 50% acetonitrile (ACN) in
40 mM NH4HCO3 and the gel pieces were dehydrated with
100% ACN for 15 minutes. The ACN was removed and the gel
pieces were further dried in a vacuum centrifuge at 62uC for
30 min. Peptides were released from the gel by trypsin digestion
(250 ng) in 30 ml of 40 mM NH4HCO3 and the samples
maintained at 4uC for 15 minutes. 50 mL of 40 mM NH4HCO3
was added and the digestion was left to continue at 37uC
overnight. The digestion was terminated with 10 ml of 5% formic
acid (FA). Following overnight digestion, the samples were
incubated at 37uC for 30 min and centrifuged for 1 min; the
supernatant was transferred to a clean polypropylene tube.
Another 80 mL of 0.5% FA was added to the gel pieces and the
extraction procedure was repeated. Resulting peptide mixtures
were purified using solid-phase extraction (C18 ZipTip; Millopore)
after sample loading in 0.05% heptafluorobutyric acid:5% FA and
elution with 4 uL 50% ACN:1% FA and 4 uL 80% ACN:1% FA,
respectively. Eluates were combined and the sample volume was
reduced to ,2 mL by vacuum centrifugation. Subsequently, 20 ml
of 0.05% heptafluorobutyric acid/1% FA:2%ACN was added as
loading buffer.
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HPLC-ESI-MS/MS analysis
A hybrid mass spectrometer consisting of a Linear Ion Trap
Mass spectrometer, LTQ, combined with a Fourier Transform
Ion Cyclotron Resonance (FT-ICR) mass spectrometer (LTQ FT
Ultra, Thermo Fisher; San Jose, CA) fitted with a PicoView
nanospray source (New Objective, Woburn, MA) was used to
perform the HPLC-ESI-MS/MS analyses. HPLC separations
were accomplished with a linear gradient as described previously
[14]. Labeled and unlabeled fragment ions of b-F1-ATPase
peptides were quantified in the LTQ analyzer of the LTQ-FT-
ICR instrument.
Initially, a full-scan spectrum was acquired followed by
collision-induced dissociation mass spectra of the 10 most
abundant ions in the survey scan to determine if there were b-
F1-ATPase peptides with a high MS signal and a leucine residue
in the sequence. No labeled-leucine peptides were detected in a
data-dependent analysis, probably as a result of low abundance of
stable-isotope-leucine enriched peptides in b-F1-ATPase. Since,
any peptide with leucine has the potential to contain labeled-
leucine, we therefore predicted that low abundance leucine-
labeled peptides can be detected using a ‘‘targeted’’ mass
spectrometry scan approach, and based on the addition of the
appropriate mass to the mass of each leucine in a detected b-F1-
ATPase peptide. A target list with various potential leucine-
containing peptide m/z values was employed, resulting in
improved efficiency in identifying stable-isotope-leucine enriched
peptides.
Tandem mass spectra were extracted from Xcalibur ‘‘RAW’’
files and charge states were assigned using the Extract_MSN script
which is a component of Xcalibur 2.0 SR2 (Thermo Fisher; San
Jose, CA). The fragment mass spectra were searched against the
IPI_RAT_v3.33 database (http://www.ebi.ac.uk/IPI/) using
Mascot (Matrix Science, London, United Kingdom, version 2.2).
The search parameters for the sample’s protein peptides were as
follows: 10 ppm mass tolerance for precursor ion masses and
0.5 Da for product ion masses; digestion with trypsin; a maximum
of two missed tryptic cleavages; variable modifications of oxidation
of methionine and phosphorylation of serine, threonine, and
tyrosine, and addition of D9 or D10 labeled-leucine. Probability
assessment of peptide assignments and protein identifications were
made through use of Scaffold (version Scaffold-01_06_17,
Proteome Software Inc., Portland, OR).
b-F1-ATPase peptides confirmation and calculation of
enrichment based on b and y fragment ion analysis
Peptides released from the trypsin digestion were considered
only if they met the following criteria: there is a leucine residue in
the amino acid sequence; detected with high intensity relative to
other peptides (top 10 peptides); assigned with .95% probability
to b-F1-ATPase (assessed through Scaffold Proteome Software);
there is no missed cleavage; and there is no methionine in the
sequence (because of methionine oxidation). There were three b-
F1-ATPase unique peptides (i.e. their amino acid sequence
matches only the b-F1-ATPase protein) that met all these criteria:
b-F1-ATPase95-109 (LVLEVAQHLGESTVR; MH
+1, mono:
1650.9), b-F1-ATPase134-143 (IPVGPETLGR; MH
+1, mono:
1038.6), and b-F1-ATPase282-294 (VALTGLTVAEYFR; MH
+1,
mono: 1439.8). The MS/MS peak areas of the following fragment
ions from these peptides were quantified (+1 charge state): b-F1-
ATPase95-109 – b8 (890.5), b9 (1003.6), b11 (1189.7); b-F1-
ATPase134-143 – y6 (672.4), y7 (729.4) and y8 (828.5); b-F1-
ATPase282-294 – b8 (755.5), b9 (826.5), b10 (955.5), b11 (1118.6).
The corresponding fragment ions MS/MS peak areas with +9 Da
mass, containing d9-leucine, from the same peptides were also
quantified. Extracted ion chromatographic peak areas correspond-
ing to d9-labeled and unlabeled fragment ions for the three
targeted b-F1-ATPase peptides were generated for the quantifi-
cation of the amounts of d9-labeled and unlabeled fragments ions
of the peptides in the b-F1-ATPase samples. Mass tolerance was
set at 0.5 Da.
Signal linearity in the detection of labeled and unlabeled
fragment ions
Following procedures described above, a muscle homogenate was
used to create four b-F1-ATPase IP samples, each containing
,2 mg of total muscle protein. Each of the four samples was
separated by SDS-PAGE and each band corresponding to the b-F1-
ATPase was cut and trypsin digested. Following trypsin digestion,
and after the peptide mixtures were purified using solid-phase
extraction, the peptide mixtures were combined to create one
sample containing an amount of b-F1-ATPase corresponding to
,8 mg of muscle protein. This sample was dried, brought to a
volume of 30 uL with loading buffer and injected into the mass
spectrometer at seven different volumes corresponding to 0.2, 0.3,
0.4, 0.5, 0.8, 1.1, and 2.3 mg of muscle protein. The specific peak
areas for d9-leucine-labeled and unlabeled fragment ions indicated
above for the b-F1-ATPase95-109, b-F1-ATPase134-143, and b-F1-
ATPase282-294 peptides were quantified.
Reproducibility of the measured b-F1-ATPase enrichment
Muscle homogenate corresponding to ,2 mg of total muscle
protein was used to perform three separate b-F1-ATPase IP
analyses. Each of the three samples containing immunoprecipi-
tated b-F1-ATPase was loaded on a separate SDS-PAGE gel lane,
and each band was treated as a separate sample. The three
samples were analyzed in separate HPLC-MS/MS runs, using the
same procedures in all three runs. The specific peak areas for d9-
leucine-labeled and unlabeled fragment ions for the b-F1-
ATPase95-109, b-F1-ATPase134-143, and b-F1-ATPase282-294 pep-
tides were quantified. The peptide enrichment was calculated by
dividing the sum of the peak areas of the labeled fragment ions by
the sum of the peak areas of the corresponding unlabeled fragment
ions.
Linearity in the measured enrichment using synthetic
peptides
To evaluate the linearity in the measured enrichment of the
IPVGPETLGR peptide (i.e. b-F1-ATPase134-143), stock solutions
containing leucine-labeled and unlabeled IPVGPETLGR synthet-
ic peptides were prepared. Given the lack of commercially
available d9-leucine, d10-leucine was used to synthesize the
leucine-labeled peptide. D10-leucine-labeled and unlabeled
IPVGPETLGR peptides were synthesized by the Proteomics
and Protein Chemistry Lab facility at Arizona State University,
and dissolved in water. MALDI and LC-MS/MS mass spectrom-
etry analyses confirmed that the synthesized peptides correspond-
ed to unlabeled and d10-leucine-labeled IPVGPETLGR peptides
(Figure S1). Stock solution containing d10-labeled peptide was
serially diluted with stock solution containing the unlabeled
peptide to create a series of eight samples spanning a wide range
of molecular ratios of labeled to unlabeled peptide. Following
solid-phase extraction, and vacuum centrifugation (procedures
described above), loading buffer was added to the samples prior to
their injection into the mass spectrometer. Peak areas for d10-
leucine-labeled and unlabeled y6-y8 fragment ions for the
IPVGPETLGR peptide were quantified. These values were used
to determine the peptide enrichment, and by dividing the sum of
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the peak areas of the labeled fragment ions by the sum of the peak
areas of the corresponding unlabeled fragment ions. The
molecular content of the d10-leucine-labeled and unlabeled stock
solutions were calculated based on the weighted amounts of the
leucine-labeled and unlabeled IPVGPETLGR peptides added to
these solutions. Given the lack of purity in the synthesized peptides
used in the preparation of the stock solutions, the calculated
enrichment of the IPVGPETLGR peptide with d10-leucine-
containing IPVGPETLGR peptide in the resultant serial dilutions
represents predicted enrichment.
Statistical analyses
Coefficient of variation (CV) values were calculated to assess the
reproducibility of the enrichment measurements of the b-F1-
ATPase peptides. Regression analysis was conducted to assess the
linear fit between variables of interest. All the statistical analyses
were performed using the MinitabH 15.1 statistical software
(Minitab Inc., State College, PA).
Results
Sequence coverage of immunoprecipitated b-F1-ATPase pro-
tein by top-10 data dependent tandem mass spectrometry
following these procedures was .70% (Figure 1). Figure 2a
illustrates the b and y fragment ions of the representative b-F1-
ATPase134-143 peptide. Figure 2b-c depicts MS/MS scans for
unlabeled and d9-leucine labeled y6-y8 fragment ions of the b-F1-
ATPase134-143 peptide, together with the corresponding extracted
ion chromatographic peak areas from muscle sample collected
from the rat infused with the stable-isotope-labeled leucine. No
peaks were detected for fragment ions with +9 Da mass in muscle
b-F1-ATPase samples from the saline infused rat for any of the
three targeted b-F1-ATPase peptides.
Signal linearity in the detection of labeled and unlabeled
fragment ions
For muscle b-F1-ATPase samples collected from the rat infused
with the stable-isotope-labeled leucine, the MS/MS peak areas
corresponding to the d9-labeled and unlabeled fragment ions of
the three targeted b-F1-ATPase peptides were quantified over a
wide range of amounts of protein/peptides injected into the LC-
MS/MS. Regression analysis was performed between the amounts
of protein analyzed, reflecting the amounts of muscle b-F1-
ATPase, and each of the d9-leucine-labeled and unlabeled
fragment ion peak areas of the three targeted b-F1-ATPase
peptides. Calculated R2 values from the regression analyses for the
b-F1-ATPase95-109 peptide corresponding to d9-labeled MS/MS
peak areas ranged between 0.94 and 0.97, and those correspond-
ing to unlabeled MS/MS peak areas ranged between 0.97 and
0.98. Regression analyses R2 values for the b-F1-ATPase282-294
peptide were between 0.62 and 0.87 for the d9-labeled MS/MS
peak areas, and between 0.71 and 0.75 for the unlabeled MS/MS
peak areas. R2 values for the ATPase134-143 peptide were 0.99
across all d9-labeled as well as unlabeled fragment ions (Figure 3).
The regression analyses also indicated that for both the b-F1-
ATPase95-109 and b-F1-ATPase282-294 peptides the y-intercept of
the regression equations describing the relationship between the
amounts of protein analyzed and fragment ion peak areas were
significantly different from zero (P,0.05) for all d9-labeled and
unlabeled fragment ions. However, none of the y-intercept values
of the regression equations describing the corresponding relation-
ships for the ATPase134-143 peptide were significantly different
from zero (P.0.05).
Reproducibility of the measured b-F1-ATPase enrichment
For each b-F1-ATPase peptide within a replicate the sum of the
peak areas of its d9-leucine-labeled fragment ions was divided by
the sum of the peak areas of its corresponding unlabeled fragment
ions in order to determine the enrichment of the specific b-F1-
ATPase peptide with d9-leucine. The average percent enrichment
based on these replicates for the b-F1-ATPase95-109 peptide was
0.564% 6 0.023% (average value 6 standard deviation), with a
CV value of 4.15%. These same measures corresponding to the b-
F1-ATPase134-143 peptide were 0.482% 6 0.014% and 2.6%,
respectively. For the b-F1-ATPase282-294 peptide the average
percent enrichment was 0.566% 6 0.051% and the CV was
8.98%.
Linearity in the measured enrichment using synthetic
peptides
Linearity in the measured enrichment was evaluated only for
the b-F1-ATPase134-143 peptide (i.e. IPVGPETLGR), because it
was the only peptide that showed acceptable linearity in the signal
intensity in the detection of labeled and unlabeled fragment ions
(based on the results reported in the ‘‘Signal Linearity in the
Detection of Labeled and Unlabeled Fragment Ions’’ section). The
measured percent enrichment (i.e. sum of y6-y8 labeled fragment
ions peak areas/sum of y6-y8 unlabeled fragment ions peak
areas*100) in the LC-MS/MS-analyzed samples prepared to
contain synthetic IPVGPETLGR peptides enriched with synthetic
IPVGPETLGR peptides that contained labeled leucine ranged
between 0.009% and 8.185%. Regression analysis indicated
Figure 1. Coverage map of tryptic peptides of b-F1-ATPase from rat muscle. The muscle was analyzed using the procedures described in
the text. Detected peptides are depicted in bold font letters. The amino acid sequence underlined identifies the representative tryptic b-F1-ATPase134-
143 peptide (i.e. IPVGPETLGR). Percent coverage is 77%.
doi:10.1371/journal.pone.0026171.g001
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Figure 2. Representative IPVGPETLGR peptide ofmuscle b-F1-ATPase and LC-MS/MS spectra for IPVGPETLGRpeptide enrichedwith d9-
leucine. Tryptic peptide IPVGPETLGR, corresponding to b-F1-ATPase134-143, showing the b and y fragment ions (A); depiction of tandemmass spectrum for
fragment ions of the IPVGPETLGR peptide showing the y6-y8 unlabeled fragment ions (left) and the corresponding extracted ion chromatographic peak
areas of these ions (right) used for the quantification of the enrichment of the IPVGPETLGR peptide (B); depiction of spectra for fragment ions of the
IPVGPETLGR peptide showing the d9-leucine-labeled fragment ions (i.e. same fragment ions as in (B) shifted by 9 m/z) (left) and the corresponding
extracted ion chromatographic peak areas of these ions (right) used for quantification of the enrichment of the IPVGPETLGR peptide (C). Fragment ions
either not containing leucine (i.e. b7) or containing leucine (i.e. b8, b9) in the sequence are also shown (B). Such ions, although they contain leucine and their
enrichment can theoretically be quantified (i.e. b8), were not taken into consideration because their relative low abundance (,10% of parent ion).
doi:10.1371/journal.pone.0026171.g002
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excellent linear relationship between the measured and predicted
IPVGPETLGR percent enrichment throughout the range of the
prepared samples (Figure 4).
Discussion
The overall goal of this study was to evaluate the reproducibility
of an LC-MS/MS approach to quantify the enrichment of in vivo-
labeled muscle b-F1-ATPase based on the enrichment of its tryptic
peptides. Measurement of this enrichment is a key methodological
step in order to evaluate the translational regulation of b-F1-
ATPase by means of stable-isotope methodology. The described
approach is based on immunoprecipitation of b-F1-ATPase,
separation of b-F1-ATPase by 1-D SDS-PAGE, and determina-
tion of the enrichment of fragment ions of selected b-F1-ATPase
peptides using LC-MS/MS.
An important finding of the present study is that two (i.e. b-F1-
ATPase95-109 and b-F1-ATPase282-294) of the three tryptic b-F1-
ATPase peptides that met our initial criteria to be used for the
determination of the reproducibility of b-F1-ATPase peptide
enrichment demonstrated low, and in some cases unacceptable
(i.e. R2 = 0.62), linearity in the signal intensity with which amounts
Figure 3. b-F1-ATPase134-143 peptide fragment ions peak areas as a function of the amount of protein analyzed. D9-leucine-labeled
fragment ions (left) and corresponding unlabeled fragment ions (right) were quantified in association with various amounts of muscle protein
processed. Data were analyzed using regression analysis. Corresponding R2 values are shown for each fragment ion. The y-intercept of the regression
equations is not significantly different from zero (P.0.05).
doi:10.1371/journal.pone.0026171.g003
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of labeled and unlabeled fragment ions were detected. For these
two peptides, there was proportionally less increase in MS/MS
fragment ion signal intensity with increased amounts of protein/
peptides injected into the LC-MS/MS. On the other hand, there
was an excellent linearity (i.e. R2 = 0.99) in the signal intensity with
which labeled and unlabeled amounts of fragment ions were
detected for the b-F1-ATPase134-143 peptide. Also, none of the y-
intercept values of the regression equations describing the MS/MS
fragment ion intensities as a function of the amounts of protein/
peptide injected into the LC-MS/MS was significantly different
from zero for the b-F1-ATPase134-143 peptide. The latter finding
further underscores an accurate detection of generated amounts of
labeled and unlabeled fragment ions for the b-F1-ATPase134-143
peptide over a wide range of labeled and unlabeled amounts of
protein analyzed. Although the specific reason(s) for the lack of
linear function in the signal intensity with which labeled and
unlabeled amounts of fragment ions were detected for the b-F1-
ATPase95-109 and b-F1-ATPase282-294 peptides are not known,
visual inspection of their MS/MS spectra showed poor quality
spectra in association with greater noise when compared to the
MS/MS spectra of the b-F1-ATPase134-143 peptide.
The results obtained with respect to the percent enrichment of the
b-F1-ATPase134-143 peptide in the reproducibility experiments
(‘‘Reproducibility of the Measured b-F1-ATPase Enrichment’’
section) are similar to those when the percent enrichment (0.470%
6 0.012%) and CV (2.6%) for the b-F1-ATPase134-143 peptide were
calculated based on the data obtained across the various amounts of
the protein/peptide analyzed in the MS/MS signal linearity
experiment (‘‘Signal Linearity in the Detection of Labeled and
Unlabeled Fragment Ions’’ section). The latter findings enhance the
results obtained from the reproducibility experiments for the b-F1-
ATPase 134-143 peptide and provide additional evidence for an
excellent reproducibility in the measurement of in vivo-labeled muscle
b-F1-ATPase enrichment using LC-MS/MSwhen this measurement
is based on the enrichment of the b-F1-ATPase 134-143 peptide. The
presence of more than one leucine residues that can be labeled with
d9-leucine in both the b-F1-ATPase95-109 and b-F1-ATPase282-294
peptides could be the reason for the poorer reproducibility of the
enrichment measurement using those two peptides. There was also
greater average percent enrichment measured using the b-F1-
ATPase95-109 and the b-F1-ATPase282-294 peptides compared to that
measured using the b-F1-ATPase 134-143 peptide that is attributed to
the existence of isobaric peptides for the b-F1-ATPase95-109 and the
b-F1-ATPase282-294. The probability of having a singly labeled
leucine in any given peptide increases with the number of amino acid
(i.e. leucine) residues that can incorporate labeled leucine, and the b-
F1-ATPase95-109 and the b-F1-ATPase282-294 peptides both contain
more than one leucine residues in their sequence.
Previously published approaches to measure the enrichment of
proteins labeled in vivo with stable isotopes in animal models [15]
were done in conjunction with high isotopic enrichment of the
proteins (i.e. feeding the animals highly enriched isotopes for very
long periods of time), none of which is practical in short-term (i.e.
only hours-long) animal or human experiments. Also, contrary to
the circumstance related to the determination of the enrichment of
a protein with a fast turnover rate such as the amyloid-b in human
cerebrospinal fluid [9], the slow turnover rate, and thus the lower
abundance of labeled b-F1-ATPase molecules in muscle, consti-
tutes a challenge to reproducibly measure the stable-isotope
enrichment of muscle b-F1-ATPase, and in a way that is practical
when investigating its kinetics in animals or humans. The present
study builds on the previously described approach [9], and extents
the methodology as well as its applicability to a muscle protein.
Evaluation of the reproducibility of the measurement of the stable-
isotope enrichment of peptides of a specific muscle protein using
LC-MS/MS is prerequisite for the use of any peptide-based
approach that is employed to measure the kinetics of such protein
in association with stable-isotope infusion experiments in animals
or humans. Our results show that the stable-isotope enrichment of
in-vivo-labeled muscle b-F1-ATPase can reliably be measured
based on the determination of the enrichment of the b-F1-
ATPase134-143 peptide.
Recently Jaleel et al. [16], have reported an MS/MS approach
to determine the stable-isotope enrichment of muscle proteins
labeled in vivo. This approach involves two separate steps, with the
first being the identification of a protein that is separated by two-
dimensional gel electrophoresis using LC-MS/MS, and the second
the measurement of the enrichment of the identified protein using
GC-MS/MS. Protein enrichment in the latter step is determined
by measuring the stable-isotope enrichment of an amino acid
following hydrolysis of the identified protein. Besides using a single
MS/MS step in the analysis of a pre-selected peptide, the
approach described herein is based on the measurement of the
stable-isotope enrichment of a unique peptide of the muscle
protein. This is important, because when determination of protein
enrichment is based on the determination of the enrichment of its
amino acids the accuracy of the measured enrichment depends on
the purity of the isolated protein in the sample (i.e. contamination
of the amino acids of the protein of interest by hydrolyzed amino
acids from unrelated proteins). A major advantage of the approach
described herein is, therefore, the specificity in the determination
of the enrichment of the protein of interest.
It is noted that the stable-isotope of the amino acid leucine
evaluated in the present study contains nine deuterium atoms,
which ensures practically zero d9-leucine b-F1-ATPase enrich-
ment at the initiation of the infusion period. Therefore, a single
muscle biopsy performed at the end of the period of interest
[17,18,19] in combination with frequent peripheral blood
sampling can be used to accurately describe the rate of synthesis
Figure 4. Relationship between measured and predicted
enrichment for the synthetic peptide IPVGPETLGR. D10-leucine
labeled and unlabeled IPVGPETLGR synthetic peptides were mixed at
eight different molar ratios, processed, and analyzed by LC-MS/MS. The
peak areas for d10-leucine-labeled and unlabeled y6-y8 fragment ions
for the IPVGPETLGR peptide were quantified. Peptide percent
enrichment was calculated by dividing the sum of the peak areas of
the labeled fragment ions by the sum of the peak areas of the
corresponding unlabeled fragment ions. Data between measured and
predicted percent enrichments were analyzed using regression analysis.
doi:10.1371/journal.pone.0026171.g004
Stable-Isotope Enrichment of b-F1-ATPase
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26171
of b-F1-ATPase. Because the same peptide (IPVGPETLGR) is
observed in muscle from both rats (b-F1-ATPase134-143) and
humans (b-F1-ATPase134-143) [13], measurement of b-F1-ATPase
enrichment based on the enrichment of this peptide is readily
applicable to human experiments. Although we have specifically
been interested in b-F1-ATPase, this approach can be applied in
the determination of the enrichment of any protein from skeletal
muscle that has been labeled in vivo, and after evaluating the
existence of a peptide that can reliably be used to describe the
enrichment of the protein of interest. With respect to the
applicability of the approach described herein only the abundance
of the protein of interest in the sample is a concern. In the present
study, 2 mg of muscle protein (i.e. 20 mg of wet muscle) are
sufficient for the determination of b-F1-ATPase enrichment.
However, a larger muscle sample can increase the overall amount
of labeled proteins found in smaller quantities in skeletal muscle.
In this regard, and although in the present studies mitochondrial
b-F1-ATPase was immunoprecipitated from whole muscle ho-
mogenate, isolation of the mitochondria can enrich the protein
homogenate with mitochondrial proteins that are targeted for
quantitative determination several fold [20].
In conclusion, our results show that the reproducibility of the
determination of the stable-isotope enrichment of a protein using
LC-MS/MS may vary based on the specific peptide chosen to
describe the protein enrichment. The b-F1-ATPase134-143 peptide
provides reproducible results for the determination of the stable-
isotope enrichment of in vivo-labeled muscle b-F1-ATPase.
Although we have been interested in the enrichment of b-F1-
ATPase, this approach can be extended in the study of numerous
other proteins from skeletal muscle.
Supporting Information
Figure S1 MALDI and LC-MS/MS mass spectrometry
analysis of synthetic peptides. Synthetic IPVGPETLGR
peptides, corresponding to the tryptic peptide of the b-F1-ATPase
(i.e. b-F1-ATPase), were prepared to contain unlabeled and d10-
labeled-leucine. The top part shows MALDI spectra for the
unlabeled synthetic peptide (A) and the labeled-leucine synthetic
peptide (B), the latter shifted by 10 Da. The bottom part shows
LC-MS/MS spectra for fragment ions for the unlabeled synthetic
peptide (C) and the labeled-leucine synthetic peptide (D), the latter
shifted by 10 Da. These mass spectrometry data provide evidence
that the synthesized peptides correspond to unlabeled and d10-
leucine-labeled IPVGPETLGR peptides.
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